Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the gross margin high or low?
The gross margin of 54.43% is in line with its 4-year average of 57.86%, near the high end of its 4-year range (0.00%–76.11%).
0.32% above its 12-month average of 54.25%.
Reported quarterly gross margin; no daily interpolation. Q2 FY2026 (2026-06-30): 64.31%.
GROSS MARGIN
54.43%
GROSS MARGIN AVG TTM
54.25%
GROSS MARGIN AVG 3Y
56.72%
GROSS MARGIN AVG 5Y
N/A
GROSS MARGIN AVG 10Y
N/A
GROSS MARGIN AVG 15Y
N/A
GROSS MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
+0.32%
CURRENT VS 3Y AVG
-4.04%
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
41.76%
median of 627 covered companies
CURRENT VS SECTOR MEDIAN
+30.34%
vs the sector median at left
Market Cap
$7.07M
Gross Margin
64.28%
TTM Avg
69.38%
3Y Avg
65.33%
5Y Avg
71.21%
Market Cap
$7.23M
Gross Margin
0.00%
TTM Avg
0.00%
3Y Avg
4.26%
5Y Avg
4.26%
Market Cap
$7.33M
Gross Margin
14.92%
TTM Avg
28.44%
3Y Avg
28.69%
5Y Avg
27.44%
Market Cap
$6.92M
Gross Margin
80.62%
TTM Avg
90.31%
3Y Avg
-419.28%
5Y Avg
-4158.68%
Market Cap
$6.93M
Gross Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$6.70M
Gross Margin
-291.27%
TTM Avg
-237.54%
3Y Avg
-120.88%
5Y Avg
-89.07%
| NAME | MARKET CAP | GROSS MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Mangoceuticals, Inc. (MGRX) | $7.01M | 54.43% | 54.25% | 56.72% | N/A |
| Co-Diagnostics, Inc. (CODX)vs › | $7.07M | 64.28% | 69.38% | 65.33% | 71.21% |
| KALA BIO, Inc. (KALA)vs › | $7.22M | 0.00% | 0.00% | 8.55% | 24.65% |
| Curanex Pharmaceuticals Inc Common Stock (CURX)vs › | $7.23M | 0.00% | 0.00% | 4.26% | 4.26% |
| InMed Pharmaceuticals Inc. (INM)vs › | $7.33M | 14.92% | 28.44% | 28.69% | 27.44% |
| Longeveron Inc. (LGVN)vs › | $7.33M | 69.76% | 72.87% | 54.39% | 49.20% |
| Bolt Biotherapeutics, Inc. (BOLT)vs › | $6.92M | 80.62% | 90.31% | -419.28% | -4158.68% |
| NeuroSense Therapeutics Ltd. (NRSN)vs › | $6.93M | 0.00% | 0.00% | 0.00% | 0.00% |
| Aclarion, Inc. (ACON)vs › | $6.70M | -291.27% | -237.54% | -120.88% | -89.07% |
| Enveric Biosciences, Inc. (ENVB)vs › | $6.67M | 0.00% | 0.00% | 0.00% | 0.00% |
Gross Margin
54.4%
(Revenue - COGS) / Revenue
Gross Margin = Gross Profit / Revenue
Gross margin is the percentage of revenue remaining after the cost of goods sold, reflecting core product profitability.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | GROSS MARGIN |
|---|---|
| 2026-06-30 | 64.31% |
| 2026-03-31 | 42.73% |
| 2025-12-31 | 50.31% |
| 2025-09-30 | 60.42% |
| 2025-06-30 | 53.51% |
| 2025-03-31 | 56.78% |
| 2024-12-31 | 76.11% |
| 2024-09-30 | 61.99% |
| 2024-06-30 | 42.77% |
| 2024-03-31 | 68.85% |
| 2023-12-31 | 58.35% |
| 2023-09-30 | 58.98% |
| 2023-06-30 | 61.69% |
| 2023-03-31 | 56.79% |
| 2022-12-31 | 54.26% |
| 2022-09-30 | 0.00% |
| 2022-06-30 | 0.00% |
| 2022-03-31 | 0.00% |
| 2021-12-31 | 0.00% |
